Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 12, 2025 • 8:31 PM ET

Date/Time Source News Release
10/24/2024 09:00 AM EDT GlobeNewswire NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma
10/21/2024 09:00 AM EDT GlobeNewswire INVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA Biosciences
10/14/2024 09:18 AM EDT GlobeNewswire INVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA)
08/14/2024 09:00 AM EDT GlobeNewswire INVO Reports Record Second Quarter 2024 Financial Results with 481% Revenue Growth and a $1.1 Million Improvement to Adjusted EBITDA
05/15/2024 04:15 PM EDT GlobeNewswire INVO Reports Record First Quarter 2024 Financial Results
04/16/2024 04:59 PM EDT GlobeNewswire INVO Reports Fourth Quarter and Full Year 2023 Financial Results
01/23/2024 08:00 AM EST GlobeNewswire NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON)
01/17/2024 08:00 AM EST GlobeNewswire INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors
12/11/2023 08:00 AM EST PR Newswire NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK(TM) Bispecific Antibody in the American Society of Hematology's Blood Journal
12/06/2023 09:00 AM EST PR Newswire NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK(TM) Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies
Page

Additional News

As of June 12, 2025 • 8:31 PM ET

Date/Time Source News Release
08/15/2024 12:14 PM EDT SeekingAlpha INVO BioScience GAAP EPS of -$0.62, revenue of $1.84M
05/21/2024 04:52 PM EDT SeekingAlpha INVO Bioscience files for $100M mixed shelf
05/16/2024 10:00 AM EDT SeekingAlpha GoodRx Holdings, Seelos Therapeutics, Clever Leaves among healthcare movers
05/16/2024 09:25 AM EDT SeekingAlpha MGNI, VERV and GWAV among pre-market gainers
05/16/2024 09:23 AM EDT SeekingAlpha INVO BioScience reports Q1 results
05/16/2024 05:36 AM EDT US Earnings Reports Expected earnings - INVO BioScience Inc.
05/14/2024 08:25 AM EDT SeekingAlpha APP, MGNX and CYCC among pre-market losers
04/23/2024 10:00 AM EDT SeekingAlpha Bio-Path Holdings, Sunshine Biopharma, INVO Bioscience among healthcare movers
04/22/2024 08:23 AM EDT SeekingAlpha SBFM, BPTH and INDO among pre-market losers
04/19/2024 10:00 AM EDT SeekingAlpha Predictive Oncology, BIMI Holdings, IMAC Holdings among healthcare movers
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.